Park YS, Lee KJ, Kim SW, Kim KM, Suh BC. Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea. J Korean Med Sci. 2017 Jul;32(7):1154-1159. doi: 10.3346/jkms.2017.32.7.1154. PMID: 28581273; PMCID: PMC5461320.
---
CDC study shows risk of Guillain-Barré syndrome elevated after Ad.26.COV2.S COVID vaccination
... some signals from the past - ignored it seems:
Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea
https://pubmed.ncbi.nlm.nih.gov/28581273/
Park YS, Lee KJ, Kim SW, Kim KM, Suh BC. Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea. J Korean Med Sci. 2017 Jul;32(7):1154-1159. doi: 10.3346/jkms.2017.32.7.1154. PMID: 28581273; PMCID: PMC5461320.
---
CDC study shows risk of Guillain-Barré syndrome elevated after Ad.26.COV2.S COVID vaccination
https://www.news-medical.net/news/20211208/CDC-study-shows-risk-of-Guillain-Barre-syndrome-elevated-after-Ad26COV2S-COVID-vaccination.aspx
Dec. 8, 2021
---
Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients
https://pubmed.ncbi.nlm.nih.gov/34644738/
Finsterer J, Scorza FA, Scorza CA. Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. Clinics (Sao Paulo). 2021 Oct 11;76:e3286. doi: 10.6061/clinics/2021/e3286. PMID: 34644738; PMCID: PMC8478139.
---
As long as we accept our role in beeing lab rats, nothing will change.
A "hint" of possible "side affeccts" - here:
5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf
Table 1. General Overview: Selected Characteristics of All Cases Received During the Reporting Interval - Fatal ( page 7 )
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
page 30 to 38 in alphapetic order
---
Mistakes were NOT made.